


# Preventing Renal Failure after Heart Surgery

Described as “must have” product by leading clinicians



## **PLEIOFLOW-RF** at a first glance

- ▶ **\$4 billion potential market**
- ▶ **Game-Changing concept based on existing known technologies**
- ▶ **No alternative procedure currently in use**
- ▶ **Founded by a Cardiac Surgeon**
- ▶ **Strong, Experienced Leadership Team and Management**
- ▶ **Funding up to Regulatory approval secured by worldwide known Foundation**
- ▶ **Collaboration with established medical device manufacturers**
- ▶ **Robust IP invented and patented by founder**
- ▶ **Clinical trials due to commence in 2021**

# The Clinical Need

**2 Million**

Patients facing Cardiac Surgery on an Annual Basis, globally

**30%**

Percentage of patients developing Acute Renal Failure postoperatively (600,000 AKI patients) <sup>1</sup>

**2%**

Percentage of patients permanently affected by Renal Failure requiring life-long dialysis (ESRF patients)

**4-6 B\$**


Total Renal Failure Costs associated with Cardiac Surgery

**15,9K\$**

Average extra cost of care per Cardiac Surgery AKI patient<sup>2</sup>

**440K\$**

Extra costs associated with End Stage Renal Failure (ESRF)<sup>3</sup> per patient



<sup>1</sup> Acute kidney injury following cardiac surgery: current understanding and future directions, O'Neal et al - Critical Care 4 July 2016

<sup>2</sup> Cost and mortality associated with postoperative acute kidney injury, Hobson et al - Annals of Surgery 1 June 2016

<sup>3</sup> Internal estimates based on \$89,000 annual cost of haemodialysis in the USA

## Pleioflow solution

**Pulsating balloon catheter combined with one-way valve increases blood flow to the kidneys.**

**Endovascular device 7-8 Fr. inserted while on CPB (2-4 hours).**

**Uses existing intra-aortic balloon pump combined with innovative valve and stent technology.**